| Literature DB >> 33062084 |
Shoji Yabuki1,2, Kozue Takatsuki2, Koji Otani1, Takuya Nikaido1, Kazuyuki Watanabe1, Kinshi Kato1, Hiroshi Kobayashi1, Jun-Ichi Handa1, Shinichi Konno1.
Abstract
Purpose: The anatomical mechanisms of cervicogenic headache caused by upper cervical lesions have been reported. However, the pathomechanisms of headache caused by lower cervical spine disorders remain unknown. The purpose of the current study was to clarify the prevalence and pathogenesis of headaches in patients with cervical spondylotic myelopathy (CSM).Entities:
Year: 2020 PMID: 33062084 PMCID: PMC7539132 DOI: 10.1155/2020/8856088
Source DB: PubMed Journal: Pain Res Manag ISSN: 1203-6765 Impact factor: 3.037
Figure 1Flow chart of subjects.
Classification of the subjects according to whether there is headache preoperatively and postoperatively.
| Type | Preoperative headache | Postoperative headache | N (male/female) (cases) |
|---|---|---|---|
| 1 | − | − | 48 (36/12) |
| 2 | − | + | 3 (3/0) |
| 3 | + | − | 10 (4/6) |
| 4 | + | + | 13 (11/2) |
−: absence, +: presence. When headache completely disappeared postoperatively, it showed − (type 3). On the other hand, when headache still existed or improved but partly remained postoperatively, it showed + (type 4).
Results of various questionnaires in each type.
| 1 ( | 3 ( | 4 ( |
| ||
|---|---|---|---|---|---|
| MPQ | 0 (0–2) | 3.5 (0–9.8) | 3 (0.5–7.5) | 0.01 | |
| NPSI | 3 (0–9) | 15 (1.5–28.8) | 10 (6–25) | 0.02 | |
| BDI | 5.5 (1–14.8) | 11 (5.8–24.8) | 13 (10.5–20) | 0.51 | |
| JOACMEQ | Cervical spine function | 75 (43.8–100) | 60 (40–100) | 35 (10–85) | 0.15 |
| Upper extremity function | 86.5 (56.8–100) | 95 (63–95) | 79 (53–89) | 0.57 | |
| Lower extremity function | 66 (55–100) | 68 (55–86) | 64 (18–86) | 0.87 | |
| Bladder function | 75 (50–94) | 75 (44–88) | 50 (19–81) | 0.23 | |
| QOL | 57 (39–69.3) | 57 (29–70 | 47 (18–50) | 0.06 | |
| SF-36 | PF | 34 (22.5–51.6) | 37.1 (28.7–45.5) | 37.5 (27–44.6) | 0.97 |
| RP | 35.8 (25.6–49.4) | 42.6 (22.2–46) | 35.8 (25.6–46) | 0.99 | |
| BP | 44.6 (39.7–61.4) | 42 (34.2–49.9) | 35.6 (35.3–43.5) | 0.04 | |
| GH | 43 (37–52.3) | 37 (30.9–44.9) | 39.7 (28.2–43.2) | 0.09 | |
| VT | 50.2 (41.8–56.4) | 48.7 (34.9–53.3) | 41 (30.3–48.7) | 0.04 | |
| SF | 50.5 (37.4–57.1) | 40.7 (29.2–52.2) | 43.9 (34.1–53.8) | 0.33 | |
| RE | 39.6 (31.1–56.6) | 39.6 (24.7–50.2) | 39.6 (26.9–43.8) | 0.59 | |
| MH | 51.8 (41.1–57.1) | 49.1 (31.2–57.1) | 43.8 (35.9–49.1) | 0.10 | |
| PCS | (20.9–48.2) | 39.2 (26–43.5) | 31.8 (10.9–40.7) | 0.65 | |
| MCS | 51 (1–14.8) | 46.7 (36.7–56.8) | 45 (37.2–52.6) | 0.01 | |
Data were shown as median (interquartile range (IQR)). MPQ: McGill Pain Questionnaire, NPSI: Neuropathic Pain Symptom Inventory, BDI: Beck Depression Index, JOACMEQ: Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire, QOL: quality of life, SF-36: MOS Short-Form 36-Item Health Survey, PF: physical functioning, RP: role physical, BP: bodily pain, GH: general health, VT: vitality, SF: social functioning, RE: role emotional, MH: mental health, PCS: physical component summary, and MCS: mental component summary.
Figure 2McGill Pain Questionnaire scores in each patient type. The scores of type 3 and type 4 patients were significantly higher than those of type 1 patients. p < 0.05.
Figure 3Neuropathic Pain Symptom Inventory scores in each patient type. The scores of type 4 patients were significantly higher than those of type 1 patients. p < 0.05.
Figure 4MOS Short-Form 36-Item Health Survey scores in each patient type. The BP (a), VT (b), and MCS (c) scores in type 4 patients were significantly lower compared with those of type 1 patients. p < 0.05, BP: bodily pain, VT: vitality, MCS: mental component summary.